Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -367.8 Million SEK | 12.83% |
| 2022 | -358.83 Million SEK | 19.55% |
| 2021 | -469.68 Million SEK | -38.43% |
| 2020 | -432.93 Million SEK | -1407.56% |
| 2019 | -30.35 Million SEK | 81.13% |
| 2018 | -130.34 Million SEK | -57.37% |
| 2017 | -84.6 Million SEK | -50.0% |
| 2016 | -56.4 Million SEK | -9.99% |
| 2015 | -51.27 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -203.82 Million SEK | -588.03% |
| 2024 Q2 | -31.5 Million SEK | 84.54% |
| 2023 Q1 | -180.07 Million SEK | -654.16% |
| 2023 FY | - SEK | 12.83% |
| 2023 Q4 | 29.41 Million SEK | 118.44% |
| 2023 Q3 | -159.57 Million SEK | -112.27% |
| 2023 Q2 | -75.17 Million SEK | 58.25% |
| 2022 Q4 | 32.49 Million SEK | 189.7% |
| 2022 Q2 | -209.84 Million SEK | -0.71% |
| 2022 Q1 | -208.36 Million SEK | 6.2% |
| 2022 FY | - SEK | 19.55% |
| 2022 Q3 | -36.22 Million SEK | 82.74% |
| 2021 Q4 | -222.13 Million SEK | -2927.56% |
| 2021 Q1 | -150.78 Million SEK | -10.92% |
| 2021 Q2 | -159.39 Million SEK | -5.72% |
| 2021 FY | - SEK | -38.43% |
| 2021 Q3 | 7.85 Million SEK | 104.93% |
| 2020 Q1 | -72.32 Million SEK | -225.79% |
| 2020 Q2 | -66.56 Million SEK | 7.97% |
| 2020 FY | - SEK | -1407.56% |
| 2020 Q4 | -135.94 Million SEK | -29.6% |
| 2020 Q3 | -104.89 Million SEK | -57.58% |
| 2019 Q4 | -22.2 Million SEK | 57.83% |
| 2019 Q2 | 85.41 Million SEK | 299.93% |
| 2019 Q3 | -52.63 Million SEK | -161.63% |
| 2019 FY | - SEK | 81.13% |
| 2019 Q1 | -42.72 Million SEK | 3.54% |
| 2018 Q4 | -44.29 Million SEK | -41.69% |
| 2018 FY | - SEK | -57.37% |
| 2018 Q3 | -31.26 Million SEK | -71.81% |
| 2018 Q2 | -18.19 Million SEK | 52.4% |
| 2018 Q1 | -38.22 Million SEK | 5.78% |
| 2017 Q3 | -17.46 Million SEK | -12.85% |
| 2017 Q1 | -10.91 Million SEK | 0.0% |
| 2017 Q2 | -15.47 Million SEK | -41.77% |
| 2017 Q4 | -40.56 Million SEK | -132.32% |
| 2017 FY | - SEK | -50.0% |
| 2016 FY | - SEK | -9.99% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Simris Alg AB (publ) | -22.36 Million SEK | -1544.694% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | -15.856% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | -30.411% |
| Xintela AB (publ) | -53.47 Million SEK | -587.855% |
| Active Biotech AB (publ) | -43.88 Million SEK | -738.068% |
| Amniotics AB (publ) | -27.14 Million SEK | -1255.057% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -2487.065% |
| BioArctic AB (publ) | 275.38 Million SEK | 233.559% |
| Camurus AB (publ) | 562.54 Million SEK | 165.382% |
| Cantargia AB (publ) | -284.31 Million SEK | -29.365% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -1778.559% |
| CombiGene AB (publ) | -35.33 Million SEK | -940.872% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | -161.129% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -2052.845% |
| Genovis AB (publ.) | 64.57 Million SEK | 669.601% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -220.088% |
| Mendus AB (publ) | -97.84 Million SEK | -275.9% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -893.418% |
| Intervacc AB (publ) | -68.98 Million SEK | -433.202% |
| Kancera AB (publ) | -61.88 Million SEK | -494.295% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -1273.27% |
| LIDDS AB (publ) | -39.67 Million SEK | -827.157% |
| Lipum AB (publ) | -37.11 Million SEK | -890.875% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -2938.69% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 1271.198% |
| NextCell Pharma AB | -40.98 Million SEK | -797.405% |
| OncoZenge AB (publ) | 7.26 Million SEK | 5161.974% |
| Saniona AB (publ) | -69.69 Million SEK | -427.732% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | -116.59% |
| Ziccum AB (publ) | -20.34 Million SEK | -1708.097% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 18390250.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | -54.79% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -17582.837% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -2638.463% |
| Corline Biomedical AB | -1.69 Million SEK | -21650.621% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | -112.205% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -571.1% |
| Aptahem AB (publ) | -10 Million SEK | -3574.639% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 3284.717% |
| Fluicell AB (publ) | -25.91 Million SEK | -1319.322% |
| Biovica International AB (publ) | -119.5 Million SEK | -207.769% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -771.076% |
| AcouSort AB (publ) | -16.7 Million SEK | -2102.018% |
| Abliva AB (publ) | -93.6 Million SEK | -292.918% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | -15.263% |
| 2cureX AB (publ) | -35.13 Million SEK | -946.798% |
| I-Tech AB | 30.34 Million SEK | 1312.071% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 48.527% |
| Cyxone AB (publ) | -20.41 Million SEK | -1701.719% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -258.997% |
| Biosergen AB | 228 Thousand SEK | 161417.105% |
| Nanologica AB (publ) | -62.11 Million SEK | -492.094% |
| SynAct Pharma AB | -222.7 Million SEK | -65.156% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -738.565% |
| BioInvent International AB (publ) | -312.7 Million SEK | -17.619% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 118971.217% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 875842.28% |
| Oncopeptides AB (publ) | -231.62 Million SEK | -58.795% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -4073.661% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -238.808% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -3106.932% |